180 related articles for article (PubMed ID: 17341621)
1. Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancer.
Reimer D; Sadr S; Wiedemair A; Goebel G; Concin N; Hofstetter G; Marth C; Zeimet AG
Ann N Y Acad Sci; 2006 Dec; 1091():270-81. PubMed ID: 17341621
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of E2F family members in ovarian cancer--an evaluation in a training set of 77 patients.
Reimer D; Sadr S; Wiedemair A; Stadlmann S; Concin N; Hofstetter G; Müller-Holzner E; Marth C; Zeimet AG
Clin Cancer Res; 2007 Jan; 13(1):144-51. PubMed ID: 17200349
[TBL] [Abstract][Full Text] [Related]
3. E2Fs mediate a fundamental cell-cycle deregulation in high-grade serous ovarian carcinomas.
De Meyer T; Bijsmans IT; Van de Vijver KK; Bekaert S; Oosting J; Van Criekinge W; van Engeland M; Sieben NL
J Pathol; 2009 Jan; 217(1):14-20. PubMed ID: 18991331
[TBL] [Abstract][Full Text] [Related]
4. E2F3a is critically involved in epidermal growth factor receptor-directed proliferation in ovarian cancer.
Reimer D; Hubalek M; Riedle S; Skvortsov S; Erdel M; Concin N; Fiegl H; Müller-Holzner E; Marth C; Illmensee K; Altevogt P; Zeimet AG
Cancer Res; 2010 Jun; 70(11):4613-23. PubMed ID: 20460525
[TBL] [Abstract][Full Text] [Related]
5. Expression of the E2F family of transcription factors during murine development.
Kusek JC; Greene RM; Nugent P; Pisano MM
Int J Dev Biol; 2000 Apr; 44(3):267-77. PubMed ID: 10853823
[TBL] [Abstract][Full Text] [Related]
6. MiR-15 and miR-16 are direct transcriptional targets of E2F1 that limit E2F-induced proliferation by targeting cyclin E.
Ofir M; Hacohen D; Ginsberg D
Mol Cancer Res; 2011 Apr; 9(4):440-7. PubMed ID: 21454377
[TBL] [Abstract][Full Text] [Related]
7. E2F1 in gliomas: a paradigm of oncogene addiction.
Alonso MM; Alemany R; Fueyo J; Gomez-Manzano C
Cancer Lett; 2008 May; 263(2):157-63. PubMed ID: 18334281
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of members of the E2F family of transcription factors in rodent testes.
El-Darwish KS; Parvinen M; Toppari J
Reprod Biol Endocrinol; 2006 Dec; 4():63. PubMed ID: 17147820
[TBL] [Abstract][Full Text] [Related]
9. Expression of the BRCA1-interacting protein Brip1/BACH1/FANCJ is driven by E2F and correlates with human breast cancer malignancy.
Eelen G; Vanden Bempt I; Verlinden L; Drijkoningen M; Smeets A; Neven P; Christiaens MR; Marchal K; Bouillon R; Verstuyf A
Oncogene; 2008 Jul; 27(30):4233-41. PubMed ID: 18345034
[TBL] [Abstract][Full Text] [Related]
10. Characterization of E2F8, a novel E2F-like cell-cycle regulated repressor of E2F-activated transcription.
Christensen J; Cloos P; Toftegaard U; Klinkenberg D; Bracken AP; Trinh E; Heeran M; Di Stefano L; Helin K
Nucleic Acids Res; 2005; 33(17):5458-70. PubMed ID: 16179649
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneous cross-talk of E2F family members is crucially involved in growth modulatory effects of interferon-gamma and EGF.
Reimer D; Sadr S; Wiedemair A; Concin N; Hofstetter G; Marth C; Zeimet AG
Cancer Biol Ther; 2006 Jul; 5(7):771-6. PubMed ID: 16721044
[TBL] [Abstract][Full Text] [Related]
12. From G0 to S phase: a view of the roles played by the retinoblastoma (Rb) family members in the Rb-E2F pathway.
Sun A; Bagella L; Tutton S; Romano G; Giordano A
J Cell Biochem; 2007 Dec; 102(6):1400-4. PubMed ID: 17979151
[TBL] [Abstract][Full Text] [Related]
13. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
[TBL] [Abstract][Full Text] [Related]
14. E2F-6 suppresses growth-associated apoptosis of human hematopoietic progenitor cells by counteracting proapoptotic activity of E2F-1.
Kikuchi J; Shimizu R; Wada T; Ando H; Nakamura M; Ozawa K; Furukawa Y
Stem Cells; 2007 Oct; 25(10):2439-47. PubMed ID: 17600109
[TBL] [Abstract][Full Text] [Related]
15. E2F - at the crossroads of life and death.
Polager S; Ginsberg D
Trends Cell Biol; 2008 Nov; 18(11):528-35. PubMed ID: 18805009
[TBL] [Abstract][Full Text] [Related]
16. Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylation-induced E2F release.
Rubin SM; Gall AL; Zheng N; Pavletich NP
Cell; 2005 Dec; 123(6):1093-106. PubMed ID: 16360038
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the Arf/p53 tumor surveillance network by E2F.
Iaquinta PJ; Aslanian A; Lees JA
Cold Spring Harb Symp Quant Biol; 2005; 70():309-16. PubMed ID: 16869767
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive assessment of E2F-1-mediated transcriptional regulation in vivo.
Monfared P; Winkeler A; Klein M; Li H; Klose A; Hoesel M; Waerzeggers Y; Korsching S; Jacobs AH
Cancer Res; 2008 Jul; 68(14):5932-40. PubMed ID: 18632648
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor-beta inhibits telomerase through SMAD3 and E2F transcription factors.
Lacerte A; Korah J; Roy M; Yang XJ; Lemay S; Lebrun JJ
Cell Signal; 2008 Jan; 20(1):50-9. PubMed ID: 17881189
[TBL] [Abstract][Full Text] [Related]
20. A lentiviral vector with expression controlled by E2F-1: a potential tool for the study and treatment of proliferative diseases.
Strauss BE; Patrício JR; de Carvalho AC; Bajgelman MC
Biochem Biophys Res Commun; 2006 Oct; 348(4):1411-8. PubMed ID: 16920066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
